Immunotherapy Study for Patients With Stage IV Melanoma

NCT02054520 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Withdrawal of IND

Conditions

Stage IV Melanoma
Metastatic Melanoma

Interventions

DRUG: HyperAcute®-Melanoma (HAM) Immunotherapy
DRUG: Ipilimumab
DRUG: Pembrolizumab
DRUG: Nivolumab

Sponsor

NewLink Genetics Corporation